2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action.
D000109:Acetylcholine / Q000378:metabolism; D001812:Blood-Brain Barrier / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D002250:Carbon Radioisotopes; D002648:Child; D002794:Choline / Q000378:metabolism; D003642:Deanol / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000009:adverse effects; D004983:Ethanolamines / Q000494:pharmacology*; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D006948:Hyperkinesis / Q000188:drug therapy; D007859:Learning Disabilities / Q000188:drug therapy; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy; D013997:Time Factors
D002250:Carbon Radioisotopes; D004983:Ethanolamines; D003642:Deanol; D004295:Dihydroxyphenylalanine; D002794:Choline; D000109:Acetylcholine